Anti-Neoplastic Agents Market Report

$5,000$10,000

Clear

Description

Product Overview
Anti-neoplastic agents are the drugs that prevent the development of neoplasm, a kind of tumor. Antineoplastic agents are also known as anticancer, chemotherapy, chemo, cytotoxic drugs. These agents are available in many forms-some are in the form of pills and others are taken as injections. These agents travel into the human body and destroy the cancerous cells and thus aids in the management of cancer. Many anti-neoplastic agents are available commercially for the therapy of various kinds of cancers including Gleevec, Oncotrex, Cytarabine, Leukeran, Near. These drugs or agents are not only used for different cancers but are used in combination with surgery, radiotherapy, immunotherapy, targeted therapy hormone therapy for many solid tumors, especially metastatic.

Market Highlights
Global Anti-Neoplastic Agents market is expected to project a notable CAGR in 2030.
Global Anti-Neoplastic Agents Market to surpass USD XXXX million by 2030 from USD XXXX million in 2019 at a CAGR of XX.X%, in the coming years i.e., 2020-30. The global Anti-Neoplastic Agents market is expected to observe growth in the future owing to increasing cases of cancers and the geriatric population. Change in lifestyle of people and the need for a cost-effective cancer cure are the key factors attributing to the growth of the antineoplastic agent’s market. Additionally, rapid innovations, increasing funding from the government, and favorable reimbursement policies are estimated to fuel the global anti-neoplastic agent market.

Global Anti-Neoplastic Agents Market: Segments
Chemotherapeutic agents’ segment to grow with the highest CAGR during 2020-30
Global Anti-Neoplastic Agents Market is segmented by Type into Chemotherapeutic agents, Biological/immunotherapeutic agent, Personalized medicine, and Others. The chemotherapeutic agents’ segment held the largest market share of XX.X% in the year 2019 and is expected to dominate the global market in the coming years. Chemotherapeutic agents are used to preventing the uncontrolled growth and proliferation of cancer cells. Easy accessibility of these drugs is expected to grow the anti-neoplastic market.

Hospital segment to grow with the highest CAGR during 2020-30
Global Anti-Neoplastic Agents Market is segmented by the end user into hospitals, clinics, research institutes, cancer rehabilitation centers, and Others. The hospital segment held the largest market share of XX.X% in the year 2019 and is expected to maintain this trend throughout the forecast period. With the increasing cases of cancer, a vast number of cancer patients are being hospitalized in hospitals every year.

Market Dynamics
Drivers
Growing Cases of Cancer
Growing incidences of cancer and an increasing geriatric population is estimated to grow the anti-neoplastic agent market. With the change in lifestyle of consumers, the risk associated with cancer is increasing. This has attracted the attention of various pharmaceutical companies to get into the anti-neoplastic agent market leading to the growth of the anti-neoplastic agents’ market globally.

Technological Advancements
Several technological advances in the field of personalized medicine offers a huge opportunity to manufacturers of anti-neoplastic agents. Additionally, due to the mounting prevalence of cancer, the multinational firms are increasing investment in cancer research which is projected to boost the global market for anti neo plastic agents.

Restraints
High Development Cost
Development of anti-neoplastic agents involves high costs due to which they are expensive. The high cost of these agents is not affordable by some consumers which are anticipated to limit the growth of global anti neoplastic agents market.

Global Anti-Neoplastic Agents Market: Key Players
Hoffmann-La Roche
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
Amgen Inc.
Bristol-Myers Squibb Company
Baxter Healthcare Corporation
Boehringer Ingelheim GmbH
Aspen Global Inc.
Bayer AG
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Pvt. Ltd.
Merc & Co.
Pfize Inc.,
Accord Healthcare, Inc.
Genentech, Inc.
Lundbeck LLC
AbbVie Inc.
Other Prominent Players
Global Anti-Neoplastic Agents Market: Regions
Global Anti-Neoplastic Agents market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, APAC, and MENA. Global Anti-Neoplastic Agents market in North America held the largest market share of XX.X% in the year 2019 owing to high prevalence of malignant neoplasm. Besides, excellent healthcare infrastructure and a number of non-government institutes offering cancer management services in this region are expected to proliferate the global anti-neoplastic market. A disorganized lifestyle coupled with an unhealthy diet is likely to increase the demand for anti-neoplastic agents in the near future.

Global Anti-Neoplastic Agents market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey and Rest of Europe
APAC Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
MENA Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa and Rest of MENA
Global Anti-Neoplastic Agents market report also contains analysis on:
Anti-Neoplastic Agents Market Segments:

By Product Type
Chemotherapeutic agents
Biological/immunotherapeutic agent
Personalized medicine
Others
By Cancer Type
Blood cancer
Breast cancer
Gastrointestinal cancer
Prostate cancer
Respiratory/lung cancer
Other
By End-user
Hospitals
Clinics
Research institutes
Cancer rehabilitation centers
Others
Anti-Neoplastic Agents Market Dynamics
Anti-Neoplastic Agents Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints

Additional information

Publisher

Geography Covered

Date Published

,

Pages

Format

Table of Contents

Contents
1. Executive Summary
2. Global Anti-Neoplastic Agents Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Anti-Neoplastic Agents Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Anti-Neoplastic Agents Market
11.1. Market Size & forecast, 2019A-2030F
11.1.1. By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.1.2. By Volume (Billion Units) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12. Global Anti-Neoplastic Agents Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2. By Product Type: Market Share (2019-2030F)
12.2.1. Chemotherapeutic agents, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.2. Biological/immunotherapeutic agent, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.3. Personalized medicine, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.2.4. Others, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3. By Cancer Type: Market Share (2019-2030F)
12.3.1. Blood cancer, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.2. Breast cancer, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.3. Gastrointestinal cancer, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.4. Prostate cancer, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.5. Respiratory/lung cancer, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.3.6. Others, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.4. By End User: Market Share (2019-2030F)
12.4.1. Hospitals, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.4.2. Clinics, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.4.3. Research Institutes, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.4.4. Cancer Rehabilitation Centers, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
12.4.5. Others, By Value (USD Billion) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
13 Company Profile
13.1. Hoffmann-La Roche
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Amgen Inc.
13.3. Bristol-Myers Squibb Company
13.4. Baxter Healthcare Corporation
13.5. Boehringer Ingelheim GmbH
13.6. Aspen Global Inc.
13.7. Bayer AG
13.8. Teva pharmaceutical Industries Ltd.
13.9. Johnson & Johnson Pvt. Ltd.
13.10. Merc & Co.
13.11. Pfize Inc.,
13.12. Accord Healthcare, Inc.
13.13. Genentech, Inc.
13.14. Lundbeck LLC
13.15. AbbVie Inc.
13.16. Other Prominent Players
14 Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

RSS
Follow by Email